Drug Trial Radar · NCT07147348
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
375
Planned (sponsor's estimate)
Start
Aug 27, 2025
Primary completion
Nov 2027
Study completion Aug 2028
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- Collaborators
- Biotheus (Hengqin) Co., Ltd.; BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
- First posted
- Aug 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this first-in-human (FIH) open-label, multi-site study is to evaluate safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary clinical efficacy of BNT3212, including identification of the recommended dose of BNT3212 for use as monotherapy and with pumitamig (also known as BNT327 or PM8002) as combination therapy, in adults with advanced solid tumors who have exhausted other treatment options.
Conditions
- Advanced Solid Tumor
Interventions
BNT3212Biological
Intravenous infusion
PumitamigBiological
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A and C - Occurrence of dose limiting toxicities (DLTs) within a participant during the DLT observation periodTime frame: Up to 28 days after first dose of investigational medicinal product (IMP).
- All parts - Percentage of participants with treatment-emergent adverse events (TEAEs) including Grade ≥3, serious, and fatal TEAEs by relationshipTime frame: From the time of the first dose of IMP until 90 days after the last dose of IMP, approximately up to 31 months.
- Parts A and C - Percentage of participants with dose interruptions or discontinuations of study treatment due to TEAEsTime frame: From the time of the first until last dose of IMP, approximately up to 31 months.
- Parts B and D - Percentage of participants with dose interruptions, reductions or discontinuations of study treatment due to TEAEsTime frame: From the time of the first until last dose of IMP, approximately up to 31 months.
- Parts B and D (expansion cohorts) - Objective response rate (ORR)Time frame: From first dose of IMP until end of study, approximately up to 31 months.
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
Cancer Research SA
Adelaide, Australia · Recruiting
Monash Medical Centre
Clayton, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Australia · Recruiting
The Alfred Hospital
Melbourne, Australia · Recruiting
One Clinical Research
Nedlands, Australia · Not yet recruiting
Scientia Clinical Research Limited
Randwick, Australia · Recruiting
Beijing Cancer Hospital
Beijing, China · Recruiting
Anhui Provincial Hospital
Hefei, China · Recruiting
First Affiliated Hospital of Xinxiang Medical University
Henan, China · Recruiting
Hunan Province Cancer Hospital
Hunan, China · Not yet recruiting
Shandong University-Jinan Central Hospital
Shandong, China · Recruiting
Qilu Hospital of Shandong University'
Shandong, China · Not yet recruiting
Linyi Tumor Hospital
Shandong, China · Recruiting
Shanghai East Hospital
Shanghai, China · Recruiting
Shanghai GoBroad Cancer Hospital
Shanghai, China · Recruiting
Sichuan Cancer Hospital
Sichuan, China · Recruiting
Zhejiang Cancer Hospital
Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.